To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
TAP Begins New Five Year Collaboration with Top Regenerative Medicine Centre
Read time: Less than a minute
The Automation Partnership (TAP) announces that its collaboration with leading translational research group, the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine at Loughborough University is to continue into a second five year phase.
This follows the recent announcement by Prime Minister, Gordon Brown and Lord Mandelson, UK Secretary of State, Department for Business, Innovation and Skills of a £5.33 million grant to the centre.
TAP’s new five year partnership with EPSRC Centre for Innovative Manufacturing in Regenerative Medicine will mean the further development and testing of its CompacT CellBase™ system for culturing clinically applicable stem cells in a Good Manufacturing Practice (GMP) environment.
Additionally, the funding will allow TAP to begin new research with the centre to develop ambr™, TAP’s advanced microscale bioreactor that mimics the characteristics of classical bioreactors. This project will enable the centre to explore the use of alternative technology platforms to ensure high quality stem cell therapies.
This new collaboration is a continuation of the work TAP began as part of the remedi (regenerative medicine – a new industry) EPSRC Grand Challenge consortium in 2005 and has contributed to remedi achieving three world firsts in automated cell culture, including production in a CompacT CellBase of a clinical grade neuronal stem cell line.
This follows the recent announcement by Prime Minister, Gordon Brown and Lord Mandelson, UK Secretary of State, Department for Business, Innovation and Skills of a £5.33 million grant to the centre.
TAP’s new five year partnership with EPSRC Centre for Innovative Manufacturing in Regenerative Medicine will mean the further development and testing of its CompacT CellBase™ system for culturing clinically applicable stem cells in a Good Manufacturing Practice (GMP) environment.
Additionally, the funding will allow TAP to begin new research with the centre to develop ambr™, TAP’s advanced microscale bioreactor that mimics the characteristics of classical bioreactors. This project will enable the centre to explore the use of alternative technology platforms to ensure high quality stem cell therapies.
This new collaboration is a continuation of the work TAP began as part of the remedi (regenerative medicine – a new industry) EPSRC Grand Challenge consortium in 2005 and has contributed to remedi achieving three world firsts in automated cell culture, including production in a CompacT CellBase of a clinical grade neuronal stem cell line.
Add Technology Networks as a preferred Google source to see more of our trusted coverage.
